ob_logo

Oxford Biomedica to expand with fourth site, creating 100 jobs

pharmafile | September 13, 2018 | News story | |  Oxford BioMedica, pharma 

Gene and cell therapy group Oxford Biomedica has announced plans to expand its business with a new site located not far from its headquarters based in its namesake city of Oxford, UK.

The new location with be the fourth opened by the company, measuring approximately 84,000 square feet; phase one and two of the firm’s expansion plans with occupy around 45,000 square feet for four GMP clean room suites and two fill and finish suites, alongside laboratories, offices and warehouses.  

Oxford Biomedica has stated that it plans to open the offices and warehouse in the first quarter of next year, with the additional clean room suites to follow a year later in the first quarter of 2020. Once the facility is fully operational, it would “more than double” the company’s bioprocessing capacity, the firm said, enabling it to rise to meet expected long-term demand and exploit immediate market opportunity. Around 100 new skilled positions are expected to emerge as a result of the expansion.

“We are delighted to secure this new facility in Oxford for our capacity expansion programme,” said John Dawson, Chief Executive Officer at the company. “Oxford BioMedica is a leading gene and cell therapy Group and, following the approval of the first gene therapy in the US, we have seen a step change in business development enquiries for our expertise across the LentiVector enabled platform. With the finances secured earlier this year, we are now able to accelerate our investment in the new facility which, once on stream, will have the capacity to meet the expected long-term demand for lentiviral vectors.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content